Financial Summary
January 1, 2021 - December 31, 2021
First Quarter
January 1, 2021 - December 31, 2021 1st Quarter
The earnings call transcript, including the Q&A session, will be available within a few business days.
January 1, 2020 - December 31, 2020
Fiscal Year
-
Consolidated Financial Summary Fiscal 2020
（601KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2020
（345KB）
-
Results Presentation Fiscal 2020
（448KB）
-
Summary of late-stage clinical trials
（566KB）
-
Revenues from other products
（25KB）
-
Transcript of FY 2020 Results/2021-2025 Medium Term Business Plan Briefing (text)
（2,712KB）
Third Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2020 Interim
（2,121KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2020 Interim
（573KB）
-
Results Presentation Fiscal 2020 Interim
（735KB）
-
Summary of clinical trials
（627KB）
-
Revenues from other products
（22KB）
-
Transcript of Results Presentation Fiscal 2020 Interim (text)
（1,274KB）
First Quarter
January 1, 2019 - December 31, 2019
Fiscal Year
-
Consolidated Financial Summary Fiscal 2019
（452KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019
（765KB）
-
Results Presentation Fiscal 2019
（1,045KB）
-
Summary of late-stage clinical trials
（187KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 (text)
（1,499KB）
Third Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2019 Interim
（251KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019 Interim
（490KB）
-
Results Presentation Fiscal 2019 Interim
（740KB）
-
Summary of late-stage clinical trials
（227KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 Interim (text)
（1,035KB）
First Quarter
IR Events
R&D Day
December 10, 2020
-
R&D Day Presentation
（1,406KB）
-
Transcript (text)
（2,871KB）
Updates on Nourianz marketing strategy in the U.S. and KW-6356 development
November 19, 2019
-
Agenda
（101KB）
-
2019 US NOURIANZ Commercial Update
（2,170KB）
-
A Phase 2a Study of KW-6356 in the Subjects with Parkinson's Disease
（1,398KB）
-
Transcript (text)
（2,086KB）
Update on KHK4083: A phase 1 study in subjects with atopic dermatitis
December 3, 2018
-
Agenda
（78KB）
-
A phase 1 study of KHK4083 in subjects with atopic dermatitis
（1,043KB）
Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU
October 27, 2017
IR News
-
May 06, 2021
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2021 First Quarter
（810KB）
-
May 06, 2021
Consolidated Financial Summary (IFRS) Fiscal 2021 First Quarter
（592KB）
-
March 31, 2021
Matters Concerning Controlling Shareholders
（119KB）
-
March 24, 2021
Corporate Governance Report
（672KB）
-
March 24, 2021
Notice Regarding Disposal of Treasury Shares Used for Restricted Share-Based Remuneration
（196KB）
